Filing Details
- Accession Number:
- 0001209191-21-004973
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-01-22 19:00:08
- Reporting Period:
- 2021-01-20
- Accepted Time:
- 2021-01-22 19:00:08
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1478320 | Adaptive Biotechnologies Corp | ADPT | Biological Products, (No Disgnostic Substances) (2836) | 270907024 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1524314 | M Chad Cohen | C/O Adaptive Biotechnologies Corp. Suite 200 Seattle WA 98102 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2021-01-20 | 50,000 | $6.32 | 51,000 | No | 4 | M | Direct | |
Common Stock | Disposition | 2021-01-20 | 11,050 | $66.82 | 39,950 | No | 4 | S | Direct | |
Common Stock | Disposition | 2021-01-20 | 33,938 | $67.35 | 6,012 | No | 4 | S | Direct | |
Common Stock | Disposition | 2021-01-20 | 5,012 | $68.33 | 1,000 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2021-01-20 | 50,000 | $0.00 | 50,000 | $6.32 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
265,000 | 2025-08-25 | No | 4 | M | Direct |
Footnotes
- The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020.
- The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $66.04 to 67.01, inclusive.
- The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $67.02 to 68.01, inclusive.
- The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $68.025 to $69.00, inclusive.
- The option is fully vested and exercisable.